Reported about 1 month ago
Eli Lilly has filed lawsuits against three medical spas and online sellers for promoting products claiming to contain tirzepatide, the active ingredient in its weight-loss medication Zepbound. These lawsuits, which cite false advertising and the safety risks posed to consumers, come after the FDA removed tirzepatide from its list of drugs in short supply. Lilly aims to prevent these vendors from selling unproven versions of the drug and seeks monetary damages.
Source: YAHOO